Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 17/20 | 0.43 |
| ▸ | HTR2A | P28223 | 14/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | HTR2C | P28335 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8337555 | 0.84 | DPP4 (0.42) | SLC6A4HTR2AKCNH2MCL1SLC6A2 | |
| SCHEMBL14036682 | 0.82 | SLC6A4 (0.37) | SLC6A4HTR2AKCNH2MCL1SLC6A2 | |
| SCHEMBL8229041 | 0.77 | SLC6A4 (0.50) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL30475257 | 0.75 | SLC6A4 (0.49) | SLC6A4HTR2AKCNH2MCL1SLC6A2 | |
| Hydrochloric Acid SCHEMBL29200951 | 0.75 | SLC6A4 (0.49) | SLC6A4HTR2AKCNH2MCL1SLC6A2 | |
| SCHEMBL18827218 | 0.75 | DPP4 (0.33) | — | |
| SCHEMBL12800814 | 0.75 | NOS3 (0.34) | MCL1 | |
| SCHEMBL12923079 | 0.73 | DPP4 (0.32) | — | |
| SCHEMBL19433173 | 0.73 | DPP4 (0.36) | HTR2AHTR2C | |
| SCHEMBL19868426 | 0.73 | DPP4 (0.32) | SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| EP-4561975-A1 | FTO INHIBITORS | RPXDS Co., Ltd (CN) | 2025-06-04 | — | — | EP | disclosed |
| CN-119546566-A | FTO inhibitors | 瑞璞鑫(苏州)生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2024022491-A1 | FTO INHIBITORS | RPXDS CO., LTD (CN) | 2024-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | FTO, LDLR, GPR119 | SLC6A4 1011/4885HTR2A 813/4885KCNH2 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.